Literature DB >> 26405331

What Is Your Institution's Position Going To Be on Biosimilars?

Danial E Baker1.   

Abstract

Year:  2015        PMID： 26405331      PMCID： PMC4568100          DOI： 10.1310/hpj5006-435

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


× No keyword cloud information.
  5 in total

1.  Biosimilars: part 2: potential concerns and challenges for p&t committees.

Authors:  C Lee Ventola
Journal:  P T       Date:  2013-06

2.  Statistical methods for assessing interchangeability of biosimilars.

Authors:  Shein-Chung Chow; Lan-Yan Yang; Aijing Starr; Shih-Ting Chiu
Journal:  Stat Med       Date:  2012-08-17       Impact factor: 2.373

3.  Biosimilars: Implications for health-system pharmacists.

Authors:  Steven D Lucio; James G Stevenson; James M Hoffman
Journal:  Am J Health Syst Pharm       Date:  2013-11-15       Impact factor: 2.637

4.  Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists.

Authors:  Niesha Griffith; Ali McBride; James G Stevenson; Larry Green
Journal:  Hosp Pharm       Date:  2014-10

Review 5.  Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know.

Authors:  Bruce E Strober; Katherine Armour; Ricardo Romiti; Catherine Smith; Paul W Tebbey; Alan Menter; Craig Leonardi
Journal:  J Am Acad Dermatol       Date:  2012-02       Impact factor: 11.527
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.